In a subgroup analysis, 99% of patient days were attack free for up to 2.7 years^1†

Photo does not depict actual patients.

* In a post-hoc analysis of 63 patients, median time to first attack in patients followed over a mean of 1.5 years in a long-term, open-label study was 223 days.²

^† In a subgroup analysis of 24 U.S. patients receiving 60 IU/kg of HAEGARDA eligible to continue the open-label extension study for >12 months.¹

HAEGARDA is the only HAE preventive therapy that delivers:

95% reduction in HAE attacks^‡

>99% less rescue medication use^3§

Replacing missing or dysfunctional C1‑INH

EXPLORE EFFICACY

The WAO Guideline for the Management of HAE states that patients should have HAE rescue medication available at all times.⁴

^‡ Median reduction in number of attacks in patients receiving 60 IU/kg of HAEGARDA vs placebo.

^§ Median reduction in rescue medication use in patients receiving 60 IU/kg of HAEGARDA vs placebo.

Get your patients started on HAEGARDA

GET PATIENTS STARTED

References: 1. Craig T, Feuersenger H, Pragst I, et al. Prophylactic therapy with subcutaneous C1-inhibitor is associated with sustained symptom control in patients with hereditary angioedema. Allergy Asthma Proc. 2022;43:202-208. 2. Craig T, Feuersenger H, Pragst I. Durability of symptom control with long-term prophylactic therapy with subcutaneous C1-inhibitor in patients with hereditary angioedema. Presented at: 33rd Annual Eastern Allergy Conference; August 16-18, 2020; Palm Beach, FL. 3. Longhurst H, Cicardi M, Craig T. COMPACT Investigators. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. N Engl J Med. 2017;376(12):1131-1140. 4. Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema — the 2021 revision and update. WAO Journal. 2022;15:1-39.

Have additional questions?

Connect with CSL Behring Medical Affairs to find additional information and ask questions.

Visit medical affairs